Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$132.59
+0.9%
$130.99
$110.86
$141.23
$230.89B0.695.35 million shs4.43 million shs
Evotec AG stock logo
EVO
Evotec
$3.50
-0.3%
$3.95
$2.84
$5.64
$1.24B1.7249,041 shs23,954 shs
Immatics N.V. stock logo
IMTX
Immatics
$5.09
-3.6%
$5.94
$3.30
$13.09
$618.69M1.02737,059 shs2.56 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$3.59
-2.7%
$3.53
$1.77
$10.72
$618.96M1.61.46 million shs1.09 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%+0.13%+5.09%-0.82%+17.43%
Evotec AG stock logo
EVO
Evotec
0.00%-3.85%-12.06%-12.50%-2.78%
Immatics N.V. stock logo
IMTX
Immatics
0.00%-10.54%-21.09%-8.62%-53.60%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
0.00%-2.71%+1.99%+19.27%-47.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.885 of 5 stars
2.54.04.24.52.42.52.5
Evotec AG stock logo
EVO
Evotec
1.8706 of 5 stars
3.32.00.00.03.20.00.6
Immatics N.V. stock logo
IMTX
Immatics
2.711 of 5 stars
3.43.00.00.03.01.70.6
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.2393 of 5 stars
3.50.00.00.03.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.91
Moderate Buy$144.478.97% Upside
Evotec AG stock logo
EVO
Evotec
2.50
Moderate Buy$5.4054.29% Upside
Immatics N.V. stock logo
IMTX
Immatics
2.83
Moderate Buy$14.67188.15% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.92
Moderate Buy$17.08375.86% Upside

Current Analyst Ratings Breakdown

Latest EVO, IMTX, ABT, and RLAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $14.00
8/15/2025
Immatics N.V. stock logo
IMTX
Immatics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/14/2025
Evotec AG stock logo
EVO
Evotec
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
8/8/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$29.00 ➝ $19.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$147.00 ➝ $142.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$142.00 ➝ $141.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$148.00 ➝ $145.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$143.00 ➝ $145.00
7/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$130.00 ➝ $140.00
7/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$145.00 ➝ $147.00
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.50$6.58 per share20.15$27.62 per share4.80
Evotec AG stock logo
EVO
Evotec
$862.40M1.44N/AN/A$2.91 per share1.20
Immatics N.V. stock logo
IMTX
Immatics
$168.65M3.67$0.24 per share20.83$5.12 per share0.99
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.01M61.83N/AN/A$4.65 per share0.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.9816.6123.142.5232.43%18.32%10.71%10/15/2025 (Estimated)
Evotec AG stock logo
EVO
Evotec
-$212.18MN/A0.00N/AN/A-20.14%-16.94%-8.14%11/5/2025 (Estimated)
Immatics N.V. stock logo
IMTX
Immatics
$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$337.71M-$1.95N/AN/AN/AN/A-41.49%-37.43%11/5/2025 (Estimated)

Latest EVO, IMTX, ABT, and RLAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q1 2025
Immatics N.V. stock logo
IMTX
Immatics
-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million
8/7/2025Q2 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.49-$0.41+$0.08-$0.41$0.07 million$0.70 million
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.26$1.26N/A$1.01$11.01 billion$11.14 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.78%N/A29.57%54 Years
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A

Latest EVO, IMTX, ABT, and RLAY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.25
1.82
1.30
Evotec AG stock logo
EVO
Evotec
0.42
1.58
1.49
Immatics N.V. stock logo
IMTX
Immatics
N/A
8.80
8.80
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
20.92
20.92

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Evotec AG stock logo
EVO
Evotec
5.81%
Immatics N.V. stock logo
IMTX
Immatics
64.41%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Evotec AG stock logo
EVO
Evotec
N/A
Immatics N.V. stock logo
IMTX
Immatics
N/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Evotec AG stock logo
EVO
Evotec
4,827355.11 millionN/ANot Optionable
Immatics N.V. stock logo
IMTX
Immatics
260121.55 millionN/AOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330172.41 million164.96 millionOptionable

Recent News About These Companies

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
HC Wainwright Issues Positive Outlook for RLAY Earnings
Equities Analysts Offer Predictions for RLAY Q3 Earnings
Brokers Offer Predictions for RLAY FY2026 Earnings
What is HC Wainwright's Forecast for RLAY FY2026 Earnings?
Relay (RLAY) Q2 Loss Narrows 41%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$132.59 +1.22 (+0.93%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$132.50 -0.09 (-0.07%)
As of 08/29/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Evotec stock logo

Evotec NASDAQ:EVO

$3.50 -0.01 (-0.28%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$3.50 +0.00 (+0.14%)
As of 08/29/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Immatics stock logo

Immatics NASDAQ:IMTX

$5.09 -0.19 (-3.60%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$5.10 +0.00 (+0.10%)
As of 08/29/2025 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$3.59 -0.10 (-2.71%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$3.58 0.00 (-0.14%)
As of 08/29/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.